临沧不孕不育怎么办检查(临沧经期推迟几天算是正常) (今日更新中)

SHENYANG, Nov. 17 (Xinhua) -- A MD-90 aircraft left the northeastern city of Shenyang for its American home on Thursday, ending the service of the last McDonnell-Douglas jet for Chinese airlines.Chinese carriers will no longer operate MD-made jets due to growing market demands, said Lu Changchun, deputy general manager with the north China branch of China Southern Airlines, which has operated the MD-90 jet for over a decade.MD-90 jets were involved in no accidents during the decade-long-service in China, so safety concerns did not lead to their retirement, Lu said, adding about 1,000 MD-90 jets are still flying around the world.Lu, however, admitted that supply of aircraft materials was affected as the production line of MD jets shrank, after McDonnell-Douglas Cooperation was merged into Boeing in 1997.MD jets were replaced mainly because Chinese airlines need new models to accommodate air travel demands fueled by the economic boom, Lu said.The north China branch of China Southern Airlines also announced Thursday the retirement of five A300-600R planes, which are replaced by A320 family jets. China Southern Airlines began flying an Airbus A380 superjumbo in China in October.China's domestic air travel market is predicted to grow 13.9 percent annually by 2014 and transport 379 million domestic air passengers, which will make the country the world's second-largest air travel market after the United States, according to a report released by the International Air Transport Association.Back in the 1990s, a Shanghai-based aircraft maker assembled two MD-90 jets in China, Lu said, adding the two jets retired this year.Change of jets model serves the strategic transformation of China Southern Airlines and meets the market demands, Lu said.Li Jiaxiang, chief of China's civil aviation administration, estimated that over 1.5 trillion yuan (235 billion U.S. dollars) will be invested in the civil aviation industry by 2015, adding about 2,000 aircraft to the country's fleet.Commercial Aircraft Corporation of China, producer of China's first self-developed jumbo jet, the C919, has announced that it will complete the design for the passenger plane in 2012. The jet is expected to take off in 2014 and put into service in 2016.

BEIJING, Jan. 1 (Xinhua) -- State Grid Corporation of China (SGCC), the country's largest power supplier, said Sunday it has put to trial operation a cross-border electricity transmission project in northeastern Heilongjiang province to supply Chinese with Russia's electric power exports.The electric power SGCC purchased from Russia began reaching Chinese customers late Saturday night after the completion of the direct-current back-to-back networking substation, or called "the trans-Amur project" by Russians, SGCC said in a statement on its website.The trial operation will last 168 hours, SGCC said in the statement.With a transmission capacity of 750 mega-watts, the electricity transmission project is China's biggest cross-border power line, according to SGCC."The implementation of the project will gain experience for the expansion of Sino-Russian energy cooperation and help promote the economic development for both countries," SGCC said.The project is also part of the Sino-Russian energy and trade cooperation.Russian Deputy Energy Minister Andrei Shishkin said in June 2011 that the transmission project would increase Russia's power supply to five or six billion kilowatt hours of electricity to China and Russia intended to increase its electricity supply to China in the coming years.Russian companies plan export 60 billion kwh of electricity to China by 2020. Power plants will be built along its border with China to reduce power transmission losses and reduce transportation costs.Also on Sunday, an oil pipeline linking Russia's far east and northeast China witnessed its one year anniversary of operation, as operators announced an accumulated 15 million tonnes of oil had been transported into China in 2011.

BEIJING, Nov. 19 (Xinhua) -- China on Saturday again called for appropriately addressing the alleged plot to assassinate the Saudi Arabian Ambassador to the United States.Foreign Ministry Spokesman Liu Weimin made the remarks in a written statement in Beijing.The UN General Assembly on Friday adopted a resolution titled "Terrorist Attacks on Internationally Protected Persons," expressing deep concern over the assassination plot and calling on Iran "to comply with all of its obligations under international law."Liu said China abstained from the vote on the resolution, because the case is highly complicated and sensitive at present and relevant parties still have different views on the issue.He said any conclusion or action must be based on comprehensive, impartial, objective and transparent investigation and substantial evidence."Before facts are checked out, parties should adopt a prudent attitude, refrain from jumping to conclusions, and avoid actions that may complicate and worsen the situation," he said.He said China hopes those countries concerned will continue to appropriately address the issue through dialogue and make joint efforts to maintain peace and stability in the Middle East and the Gulf Region.Liu also reaffirmed that China opposes all forms of terrorism, and always stands for compliance with international law and the basic norms governing international relations in handling state-to-state relations as well as the effective protection of the safety of diplomatic personnel.Chinese Permanent Representative to the United Nations Li Baodong previously addressed the UN General Assembly on Friday in order to explain China's position on the issue after he abstained from voting on the draft resolution.

WASHINGTON, Nov. 24 (Xinhua) -- An inexpensive drug that treats Type 2 diabetes has been shown to prevent a number of natural and man-made chemicals from stimulating the growth of breast cancer cells, according to a newly published study by a Michigan State University researcher. The research, led by pediatrics professor James Trosko and colleagues from South Korea's Seoul National University, provides biological evidence for previously reported epidemiological surveys that long-term use of the drug metformin for Type 2 diabetes reduces the risk of diabetes-associated cancers, such as breast cancers.The research appeared online this week in PLoS One.For the study, Trosko and colleagues focused on the concept that cancers originate from adult human stem cells and that there are many natural and man-made chemicals that enhance the growth of breast cancer cells. Using culture dishes, they grew miniature human breast tumors, or mammospheres, that activated a certain stem cell gene. Then the mammospheres were exposed to natural estrogen -- a known growth factor and potential breast tumor promoter -- and man-made chemicals that are known to promote tumors or disrupt the endocrine system.The team found that estrogen and the chemicals caused the mammospheres to increase in numbers and size. However, with metformin added, the numbers and size of the mammospheres were dramatically reduced. While each of the chemicals enhanced growth by different means, metformin seemed to be able to inhibit their stimulated growth in all cases."While future studies are needed to understand the exact mechanism by which metformin works to reduce the growth of breast cancers, this study reveals the need to determine if the drug might be used as a preventive drug and for individuals who have no indication of any existing cancers," Trosko said.

WASHINGTON, Oct. 9 (Xinhua) -- U.S. researchers have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication Sunday in Nature Biotechnology, researchers describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage."The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, of the Massachusetts General Hospital (MGH) Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes -- an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such as heart disease and cancer."Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. However, the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location.To make sure that their siRNA preparation targeted the right monocytes, researchers first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets."These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCR2 receptor. That makes a big difference."

来源：资阳报